Drilldown: Medicines

None (2) · Ketoconazole (1) · Pramipexole (1) · Ropinirole (1)

Ajovy (1) · Emgality (1) · Mirapex (IR), Mirapex ER (1) · Nizoral (oral discontinued in US for most fungal indications; topical still widely available) (1) · Requip (IR), Requip XL (extended-release) (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Antifungals|Antifungal (imidazole)]] (1) · [[:Category:Antiparkinsonians|Antiparkinsonian]] (2) · [[:Category:Dopamine agonists|Dopamine D2/D3 receptor agonist (non-ergot)]] (2) · [[:Category:Topical_antifungals|Topical antifungal]] (1)

None (3) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) · '"`UNIQ--vote-00000884-QINU`"', '"`UNIQ--vote-00000885-QINU`"', '"`UNIQ--vote-00000886-QINU`"', '"`UNIQ--vote-00000887-QINU`"' (1)

225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed (1) · Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed (1) · Topical 2% shampoo twice weekly for seborrheic dermatitis or tinea versicolor; oral use restricted by 2013 FDA action to indications where alternatives have failed (1)

1% (OTC), 2% (Rx) shampoo; 2% cream; 2% gel; 200 mg oral tablet (rarely used now) (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg (1) · IR tablets 0.25, 0.5, 1, 2, 3, 4, 5 mg; XL tablets 2, 4, 6, 8, 12 mg (1)

24 mg/day (Parkinson disease); 4 mg/day (restless legs syndrome) (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 4.5 mg/day (Parkinson disease); 0.5 mg/day (restless legs syndrome) (1) · 675 mg/quarter (1) · Topical: regimen-specific; oral: 400 mg/d in remaining specialty indications (1)

gel); oral (restricted) (1) · Oral (2) · shampoo (1) · Subcutaneous (2) · Topical (cream (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

Hours per application (topical); 24 hours (oral) (1) · Monthly dosing (1) · Monthly or quarterly dosing (1) · TID dosing (IR); once-daily (ER) (1) · TID dosing (IR); once-daily (XL) (1)

8-12 hours (longer in elderly and renal impairment)'"`UNIQ--ref-0000001B-QINU`"' (1) · Topical: not meaningfully described; oral 2-8 hours'"`UNIQ--ref-00000888-QINU`"' (1) · ~27 days (1) · ~31 days (1) · ~6 hours'"`UNIQ--ref-00000015-QINU`"' (1)

>90% (oral)'"`UNIQ--ref-0000001C-QINU`"' (1) · Not formally established (1) · Not formally established (high SC) (1) · Topical: minimal systemic; oral: pH-dependent, requires gastric acid'"`UNIQ--ref-00000889-QINU`"' (1) · ~55% (oral)'"`UNIQ--ref-00000016-QINU`"' (1)

Limited data; avoid (2) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited human data; rarely indicated in pregnancy given the typical patient population.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Topical generally safe; oral avoided.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (1% shampoo) and [[USLegal:Prescription only|Rx-only]] (higher strengths, oral) in US. Oral form carries a '''Boxed Warning''' for hepatotoxicity and is restricted by FDA to refractory fungal infections where no alternatives are available (1) · Rx (2) · [[USLegal:Prescription only|Rx-only]] in US (2)